Page 1756 - Williams Hematology ( PDFDrive )

1730 Part XI: Malignant Lymphoid Diseases Chapter 106: Essential Monoclonal Gammopathy 1731

233. Sackmann F, Pavlovsky MA, Corrado C, et al: Prognostic factors in monoclonal gam- 258. Turesson I: Nucleolar size in benign and malignant plasma cell proliferation. Acta Med
mopathy of undetermined significance. Haematologica 93:153, 2008. Scand 197:7, 1975.
234. Rosiñol L, Cibeira MT, Montoto S, et al: Monoclonal gammopathy of undetermined 259. Dehou MF, Schots R, Lacor P, Arras N, et al: Diagnostic and prognostic value of the
significance: Predictors of malignant transformation and recognition of an evolving MB2 monoclonal antibody in paraffin-embedded bone marrow sections of patients
type characterized by a progressive increase in M protein size. Mayo Clin Proc 82:428, with multiple myeloma and monoclonal gammopathy of undetermined significance. J
2007. Clin Pathol 94:287, 1990.
235. Olteanu H, Wang HY, Chen W, et al: Immunophenotypic studies of monoclonal gam- 260. French M, Fench P, Remy F, et al: Plasma cell proliferation in monoclonal gammopathy:
mopathy of undetermined significance. BMC Clin Pathol 8:13, 2008. Relations with other biologic variables—Diagnostic and prognostic significance. Am J
236. Hillengass J, Weber MA, Kilk K, et al: Prognostic significance of whole-body MRI Med 98:60, 1995.
in patients with monoclonal gammopathy of undetermined significance. Leukemia 261. Amiel A, Kirgner I, Gaber E, et al: Replication pattern in cancer: Asynchronous repli-
28:174, 2014. cation in multiple myeloma and in monoclonal gammopathy. Cancer Genet Cytogenet
237. Zhan F, Barlogie B, Arzoumanian V, et al: Gene-expression signature of benign mono- 108:32, 1999.
clonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 262. Almeida J, Orfao A, Mateo G, et al: Immunophenotype and DNA content character-
109:1692, 2007. istics of plasma cells in multiple myeloma and monoclonal gammopathy of undeter-
238. Kyle RA, Rajkumar SV: Monoclonal gammopathy of undetermined significance and mined significance. Pathol Biol 47:119, 1999.
smoldering multiple myeloma. Hematol Oncol Clin North Am 21:1093, 2007. 263. Yasuda N, Kanoh T, Uchino H: J chain synthesis in human myeloma cells: Light and
239. Barlogie B, van Rhee F, Shaughnessy JD Jr, et al: Seven year median time to progression electron microscopic studies. Clin Exp Immunol 40:573, 1980.
with thalidomide for smoldering myeloma: Partial response identifies subset requiring 264. Cassuto JP, Hammore JC, Pastorelli E, et al: Plasma cell acid phosphatase, a discrimina-
earlier salvage therapy for symptomatic disease. Blood 112:3122, 2008. tive test for benign and malignant monoclonal gammopathies. Biomedicine 27:97, 1977.
240. Cherry BM, Costello R, Zingone A, et al: Immunoparesis and monoclonal gammop- 265. Sonneveld P, Durie BGM, Lokhorst HM, et al: Analysis of multidrug-resistance (MDR-1)
athy of undetermined significance are disassociated in advanced age. Am J Hematol glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple
88:89, 2013. myeloma. Br J Haematol 83:63, 1993.
241. Bacher U, Haferlach T, Kern W, et al: Correlation of cytomorphology, immunopheno- 266. Zandecki N, Facon T, Bernard F, et al: CD19 and immunophenotype of bone marrow
typing, and interphase fluorescence in situ hybridization in 381 patients with mono- plasma cells in monoclonal gammopathy of undetermined significance. J Clin Pathol
clonal gammopathy of undetermined significance and 301 patients with plasma cell 48:548, 1995.
myeloma. Cancer Genet Cytogenet 203:169, 2010. 267. Sezer O, Heider U, Zavrski I, Possinger K: Differentiation of monoclonal gammopathy
242. Agarwal A, Ghobrial IM: Monoclonal gammopathy of undetermined significance and of undetermined significance and multiple myeloma using flow cytometric characteris-
smoldering multiple myeloma: A review of the current understanding of epidemiology, tics of plasma cells. Haematologica 86:837, 2001.
biology, risk stratification, and management of myeloma precursor disease. Clin Cancer 268. Majumdar G, Heard SE, Singh AK: Use of cytoplasmic 5′nucleotidase for differentiating
Res 19:985, 2013. malignant from benign monoclonal gammopathies. J Clin Pathol 43:891, 1990.
243. Probst LE, Hoffman E, Cherian MG, et al: Ocular copper deposition associated with 269. Van de Berg BC, Michaux L, Lecouvet FE, et al: Nonmyelomatous monoclonal gammo-
benign monoclonal gammopathy and hypercupremia. Cornea 15:94, 1996. pathy: Correlation of bone marrow MR images with laboratory findings and spontane-
244. Secundo W, Seifert P: Monoclonal corneal gammopathy: Topographic considerations. ous clinical outcome. Radiology 202:249, 1997.
Ger J Ophthalmol 5:262, 1996. 270. Bellaiche L, Laredo J-D, Lioté F, et al: Magnetic resonance appearance of monoclonal
245. Baldini L, Guffanti A, Cesana BM, et al: Role of different hematologic variables in defin- gammopathies of unknown significance and multiple myeloma. Spine (Phila Pa 1976)
ing the risk of malignant transformation in monoclonal gammopathy. Blood 87:92, 22:2551, 1997.
1996. 271. Laroche M, Attal M, Pouilles JM, et al: Dual-energy x-ray absorption in patients with
246. Bataille R: New insights in the clinical biology of multiple myeloma. Semin Hematol multiple myeloma and benign gammopathies. Clin Exp Rheumatol 14:108, 1996.
34:23, 1997. 272. Bataille R, Chappard D, Basle M: Quantifiable excess of bone resorption in monoclonal
247. Witzig TE, Gonchoroff NJ, Katzmann JA, et al: Peripheral blood B cell labeling indices gammopathy is an early symptom of malignancy: A prospective study of 87 bone biop-
are a measure of disease activity in patients with monoclonal gammopathies. J Clin sies. Blood 87:4762, 1996.
Oncol 6:1041, 1988. 273. Pecherstorfer M, Seibel MJ, Woitge HW, et al: Bone resorption in multiple myeloma
248. Yi Q, Eriksson I, He W, et al: Idiotype-specific T lymphocytes in monoclonal gammop- and in monoclonal gammopathy of undetermined significance: Quantification by uri-
athies: Evidence for the presence of CD4+ and CD8+ subsets. Br J Haematol 96:338, nary pyridinium cross-links of collagen. Blood 90:3743, 1997.
1997. 274. Ong F, Kaiser U, Seelen PJ, et al: Serum neural cell adhesion molecule differentiates
249. Yi Q, Osterborg A, Bergenbrant S, et al: Idiotype-reactive T-cell subsets and tumor load multiple myeloma from paraproteinemias due to other causes. Blood 87:712, 1996.
in monoclonal gammopathies. Blood 86:3043, 1995. 275. Lacy MQ, Donovan KA, Heimbach JK, et al: Comparison of interleukin-1 beta expres-
250. Halapi E, Werner A, Wahlstrom J, et al: T cell repertoire in patients with multiple mye- sion by in situ hybridization in monoclonal gammopathy of undetermined significance
loma and monoclonal gammopathy of undetermined significance: Clonal CD8+ T cell and multiple myeloma. Blood 93:300, 1999.
expansions are found preferentially in patients with a low tumor burden. Eur J Immunol 276. Greco C, Ameglio F, Alvino S, et al: Selection of patients with monoclonal gammopathy
27:2245, 1997. of undetermined significance is mandatory for a reliable use of interleukin-6 and other
251. Corso A, Castelli G, Pagnucco G, et al: Bone marrow T-cell subsets in patients with nonspecific multiple myeloma serum markers. Acta Haematol 92:1, 1994.
monoclonal gammopathies: Correlation with clinical stage and disease. Haematologica 277. Mathiot C, Mary JY, Tartour E, et al: Soluble CD16 (sCD16), a marker of malignancy in
82:43, 1997. individuals with monoclonal gammopathy of undetermined significance (MGUS). Br J
252. Miguel-Garcia A, Matutes E, Tarin F, et al: Circulating Ki-67 positive lymphocytes in Haematol 95:660, 1996.
multiple myeloma and benign monoclonal gammopathy. J Clin Pathol 48:835, 1995. 278. Gaillard JP, Bataille R, Brailly H, et al: Increased and highly stable levels of functional
253. Billadeau D, Van Ness B, Kimlinger T, et al: Clonal circulation cells are common in soluble interleukin-6 receptor levels in sera of patients with monoclonal gammopathy.
plasma cell proliferative disorders: A comparison of monoclonal gammopathy, smol- Eur J Immunol 23:820, 1993.
dering myeloma, and active myeloma. Blood 88:289, 1996. 279. DuVillard L, Guiguet M, Casasnovas R-O, et al: Diagnostic value of serum IL-6 level in
254. Isaksson E, Bjockholm M, Holm G, et al: Blood clonal B-cell excess in patients with monoclonal gammopathies. Br J Haematol 89:243, 1995.
monoclonal gammopathy of undetermined significance (MGUS): Association with 280. Cozzolino F, Torcia M, Aldinucci D, et al: Production of interleukin-1 by bone marrow
malignant transformation. Br J Haematol 92:71, 1996. myeloma cells. Blood 74:380, 1989.
255. Sawanoborj M, Suzuki K, Nakagawa Y, et al: Natural killer cell frequency and serum 281. Donovan KA, Lacy MQ, Kline MP, et al: Contrast in cytokine expression between
cytokine levels in monoclonal gammopathies: Correlation of bone marrow granular patients with monoclonal gammopathy of undetermined significance or multiple mye-
lymphocytes to prognosis. Acta Haematol 98:150, 1997. loma. Leukemia 12:593, 1998.
256. Leo E, Kropff M, Lindemann A, et al: DNA aneuploidy, increased proliferation and 282. Diamond T, Levy S, Smith A, et al: Non-invasive markers of bone turnover and plasma
nuclear area of plasma cells in monoclonal gammopathy of undetermined significance cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gam-
and multiple myeloma. Anal Quant Cytol Histol 17:113, 1995. mopathies of undetermined significance. Intern Med 31:272, 2001.
257. Pérez-Persona E, Vidriales MB, Mateo G, et al: New criteria to identify risk of progres- 283. Seidl S, Ackerman J, Kaufmann H, et al: DNA methylation analysis identifies the E-
sion in monoclonal gammopathy of uncertain significance and smoldering multiple cadherin gene as a potential marker of disease progression in patients with monoclonal
myeloma based on multiparameter flow cytometry analysis of bone marrow plasma gammopathy. Cancer 100:2598, 2004.
cells. Blood 110:2586, 2007.

Kaushansky_chapter 106_p1721-1732.indd 1731 9/21/15 12:40 PM